See more : Capstar Special Purpose Acquisition Corp. (CPSR) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclerion Therapeutics, Inc. (CYCN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclerion Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- E79 Gold Mines Limited (E79.AX) Income Statement Analysis – Financial Results
- Associated British Foods plc (ASBFY) Income Statement Analysis – Financial Results
- Shaanxi Baoguang Vacuum Electric Device Co., Ltd. (600379.SS) Income Statement Analysis – Financial Results
- Lucara Diamond Corp. (LUCRF) Income Statement Analysis – Financial Results
- Go Fashion (India) Limited (GOCOLORS.NS) Income Statement Analysis – Financial Results
Cyclerion Therapeutics, Inc. (CYCN)
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 297.00K | 3.32M | 2.30M | 4.51M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 65.00K | 472.00K | 0.00 | 0.00 | 1.53M | 1.75M | 2.17M |
| Gross Profit | 0.00 | 232.00K | 2.85M | 2.30M | 4.51M | -1.53M | -1.75M | -2.17M |
| Gross Profit Ratio | 0.00% | 78.11% | 85.78% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.52M | 31.49M | 37.64M | 56.41M | 95.14M | 87.72M | 78.80M | 50.90M |
| General & Administrative | 8.13M | 14.50M | 20.62M | 28.82M | 34.40M | 27.54M | 15.12M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.13M | 14.50M | 20.62M | 28.82M | 34.40M | 27.54M | 15.12M | 10.48M |
| Other Expenses | 0.00 | -1.33M | -622.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.65M | 44.67M | 57.63M | 85.23M | 129.54M | 115.25M | 93.92M | 61.38M |
| Cost & Expenses | 9.65M | 44.67M | 57.63M | 85.23M | 129.54M | 115.25M | 93.92M | 63.55M |
| Interest Income | 358.00K | 294.00K | 0.00 | 588.00K | 2.03M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 294.00K | 16.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -2.95M | 65.00K | 472.00K | 2.30M | 2.70M | 1.53M | 1.75M | 2.17M |
| EBITDA | -12.59M | -18.18M | -55.20M | -81.27M | -122.34M | -113.72M | -92.18M | -61.38M |
| EBITDA Ratio | 0.00% | -14,918.18% | -1,621.75% | -3,709.97% | -2,714.38% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.65M | -44.37M | -55.20M | -81.27M | -125.04M | -115.25M | -93.92M | -63.55M |
| Operating Income Ratio | 0.00% | -14,940.07% | -1,662.50% | -3,539.42% | -2,774.28% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.95M | 294.00K | 3.55M | 3.46M | 2.03M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -12.59M | -44.08M | -51.65M | -77.80M | -123.01M | -115.25M | -93.92M | -63.55M |
| Income Before Tax Ratio | 0.00% | -14,841.08% | -1,555.63% | -3,388.59% | -2,729.27% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -294.00K | 16.00K | -5.13M | -2.03M | 1.37M | 0.00 | 0.00 |
| Net Income | -21.02M | -43.78M | -51.66M | -72.67M | -120.98M | -115.25M | -93.92M | -63.55M |
| Net Income Ratio | 0.00% | -14,742.09% | -1,556.11% | -3,165.07% | -2,684.25% | 0.00% | 0.00% | 0.00% |
| EPS | -8.99 | -20.15 | -26.40 | -47.80 | -88.37 | -84.42 | -68.80 | -46.39 |
| EPS Diluted | -8.99 | -20.15 | -26.40 | -47.80 | -88.37 | -84.42 | -68.80 | -46.39 |
| Weighted Avg Shares Out | 2.34M | 2.17M | 1.96M | 1.52M | 1.37M | 1.37M | 1.37M | 1.37M |
| Weighted Avg Shares Out (Dil) | 2.34M | 2.17M | 1.96M | 1.52M | 1.37M | 1.37M | 1.37M | 1.37M |
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C.
Cyclerion Announces Leadership Transitions
Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
Washington Business Journal Ranks Intelligent Waves Amongst Largest Veteran-Owned Companies in 2020
Superior Group Looks Like A Winner (NASDAQ:SGC)
Critical Review: Abeona Therapeutics (NASDAQ:ABEO) versus Cyclerion Therapeutics (NASDAQ:FBRX)
China to become "export destination country number one" for Germany: IW
How R&D Expenses Can Help You Pick Outperforming Stocks
Angela Merkel crisis: Germany dealt devastating blow after shocking prediction
Das Neuste zur Coronakrise - BAG vermeldet 62 neue Ansteckungen
Source: https://incomestatements.info
Category: Stock Reports